The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group

Basit Öğe Kaydı
dc.contributor.authorAraz, Murat
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorKorkmaz, Levent
dc.contributor.authorBeypinar, Ismail
dc.contributor.authorUysal, Mukremin
dc.date.accessioned2024-02-23T14:02:41Z
dc.date.available2024-02-23T14:02:41Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractPurpose: We aimed to investigate the compliance of Turkish Medical Oncologists to antiemetic guidelines for treatment of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving high (HEC), moderate (MEC), and low (LEC) emetogenic chemotherapy. Method: A covering electronic mail letter with an online questionnaire link was sent to e-mail and mobile application groups including all 599 members of the Turkish Society of Medical Oncology in January 2018. The online survey has consisted of twelve questions. Results: Questionnaire form was responded by 146 of Turkish Medical Oncologists. The most of the participants were following up more than one antiemetic guideline (53%). While compliance with the antiemetic guidelines was higher in acute CINV prophylaxis for HEC and MEC, it was significantly lower in the delayed CINV treatment of HEC and LEC. The highest and lowest compliance rate was found in the prophylaxis of acute and delayed CINV of HEC (92% and 15%, respectively). The incidence of noncompliance for delayed CINV in HEC was statistically significantly higher in those who worked for <= five years in an oncology department, under 39 years of age, and non-academicians (p = 0.004, p = 0.042, p = 0.005, respectively). Conclusions: Noncompliance with the antiemetic guidelines is continue to be a big problem in Turkish Medical Oncologists. The use of standardized antiemetic protocols in chemotherapy order forms or a computerized decision-support system is now seen as a better tool to enhance compliance with the guidelines. (C) 2018 Elsevier Inc. All rights reserved.en_US
dc.description.sponsorshipTurkish Society of Medical Oncology and Turkish Oncology Group (TOG)en_US
dc.description.sponsorshipWe thank for their support to the Turkish Society of Medical Oncology and Turkish Oncology Group (TOG).en_US
dc.identifier.doi10.1016/j.currproblcancer.2018.09.002
dc.identifier.endpage353en_US
dc.identifier.issn0147-0272
dc.identifier.issn1535-6345
dc.identifier.issue4en_US
dc.identifier.pmid30497851en_US
dc.identifier.scopus2-s2.0-85057139011en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage344en_US
dc.identifier.urihttps://doi.org/10.1016/j.currproblcancer.2018.09.002
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11810
dc.identifier.volume43en_US
dc.identifier.wosWOS:000486135200012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMosby-Elsevieren_US
dc.relation.ispartofCurrent Problems In Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntiemetic Guidelinesen_US
dc.subjectChemotherapy-Induced Nausea And Vomitingen_US
dc.subjectComplianceen_US
dc.subjectOncologisten_US
dc.titleThe compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Groupen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu